Ondansetron Inovamed

/ Inovamed

The recommended dose for oral administration is 8 mg to be taken twice daily.

For the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.
For prevention and treatment of postoperative nausea and vomiting in adults.

Concomitant use with apomorphine. Hypersensitivity to any component of the preparation.

Hypersensitivity (including respiratory events). Ondansetron prolongs the QT interval in a dose dependant manner. Hypokalaemia and hypomagnesaemia should be corrected prior to ondansetron administration. There have been post-marketing reports describing  patients with serotonin syndrome. Patients with signs of subacute intestinal obstruction should be monitored following administration. In patients with adenotonsillar surgery prevention of nausea and vomiting with ondansetron may mask occult bleeding. Paediatric patients receiving ondansetron with hepatotoxic chemotherapeutic agents should be monitored closely for impaired hepatic function. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Please refer to the license holder for further details.

Headache, sensation of warmth or flushing, constipation.
Please refer to the license holder for further details.

Use with caution with: phenytoin, carbamazepine, rifampicin, tramadol.
Please refer to the license holder for further details